系统性硬化病抗纤维化的靶向治疗进展  

Targeted therapies against fibrosis in systemic sclerosis

作　　者：辛崇美[1] 崔祥祥[1] 李明[1] 

机构地区：[1]复旦大学附属中山医院皮肤科,上海200032

出　　处：《国际皮肤性病学杂志》2014年第6期349-352,共4页International Journal of Dermatology and Venereology

摘　　要：纤维硬化是系统性硬化病的一个重要特征.活化的成纤维细胞产生过多的胶原纤维导致皮肤及内脏器官的纤维硬化,影响患者的生活质量,甚至导致患者死亡.由于缺少有效治疗纤维化的方法,其发病机制及治疗方案需进一步的研究及评估.主要概述纤维硬化过程中,针对组织内各种细胞异常及调节靶点如阻断炎症反应、抑制促纤维化因子、调节表观遗传信号转导及干扰形态形成途径等方面对抗纤维化的靶向治疗.Fibrosis is a key feature of systemic sclerosis （SSc） and arises from excessive production of collagen fibers by pathologically activated fibroblasts.It can affect the skin and many internal organs,negatively influence the quality of life,and even threaten the life of patients.Since effective therapies for fibrosis are unavailable,further studies are still needed to elucidate the pathogenesis of and to evaluate treatment strategies for,SSc.This review mainly focuses on some therapies targeting various cellular abnormalities and regulatory factors during fibrosclerosis,which can counteract fibrosis by blocking inflammatory pathways,inhibiting profibrotic growth factors,modulating epigenetic signaling transduction,and interfering with morphogenic pathways.

关 键 词：硬皮病 系统性 纤维化 分子靶向治疗 

分 类 号：R593[医药卫生—内科学]